Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1, 12.2010
- Urheber
-
Marcelin, AG
- Beteiligte Personen und Organisationen
-
Charpentier, C.
Ferreira, C.
Wirden, M.
Lemarchand, C.
Descamps, D.
CALVEZ, V.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-13-S4-P136
- URN
-
urn:nbn:de:1111-2016052059105
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Marcelin, AG
- Charpentier, C.
- Ferreira, C.
- Wirden, M.
- Lemarchand, C.
- Descamps, D.
- CALVEZ, V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
Virological and immunological response to three boosted protease inhibitor regimens
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Merger failures
Merger failures
Photographic failures
Merger failures
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
Virological and immunological response to three boosted protease inhibitor regimens
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Merger failures
Merger failures
Photographic failures
Merger failures
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
Virological and immunological response to three boosted protease inhibitor regimens
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Merger failures
Merger failures
Photographic failures
Merger failures
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam